Omeros reports Q3 2022 net loss $17.5M; FDA denies narsoplimab appeal, provides resubmission path

OMEROS CORP

2022-Q3 EPS reported -$1.30

Net loss $17.5M ($0.28/share) vs $22.7M loss in 3Q21; cash and equivalents $221M at Sept 30.
FDA denied Formal Dispute Resolution for narsoplimab BLA; proposes resubmission with survival vs historical control.
Sold interest in OMIDRIA royalties to DRI for $125M cash; max DRI payout $188.4M at 9.4% effective rate.
CMS final rule confirms separate OMIDRIA payment in ambulatory surgical centers for 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OMEROS CORP reported financial results for three and nine months ended September 30, 2022.

Period: three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 9, 2022, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001558370-22-017140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.